Trials / Recruiting
RecruitingNCT07349069
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer
A Randomized, Open-Label, Phase III Trial to Compare HRS-8080 Versus Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer Who Have Received at Least 2 Years of Standard Adjuvant Endocrine Therapy
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4,800 (estimated)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy and safety of HRS-8080 in patients with high-risk early breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-8080 Tablets | HRS-8080 tablets. |
| DRUG | Letrozole tablets | Letrozole tablets. |
| DRUG | Tamoxifen Citrate Tablets | Tamoxifen Citrate tablets. |
Timeline
- Start date
- 2026-03-04
- Primary completion
- 2030-12-01
- Completion
- 2034-01-01
- First posted
- 2026-01-16
- Last updated
- 2026-03-19
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07349069. Inclusion in this directory is not an endorsement.